What is the recommended duration of betahistine therapy for benign paroxysmal positional vertigo?

Duration of Betahistine for BPPV

Betahistine should NOT be routinely prescribed for BPPV, and if used at all, should be limited to short-term symptom management only—typically no more than 1-4 weeks—because canalith repositioning procedures (CRP) are the definitive first-line treatment and betahistine provides no proven benefit over CRP alone. 1

Why Betahistine Is Not Recommended for BPPV

Guideline Position on Vestibular Suppressants

• The American Academy of Otolaryngology-Head and Neck Surgery explicitly recommends against routinely prescribing vestibular suppressant medications (including antihistamines like betahistine) for BPPV treatment, because there is no evidence that these medications work as definitive primary therapy 1
• Vestibular suppressants may only be considered for short-term management of severe autonomic symptoms (nausea, vomiting) in severely symptomatic patients, not as a treatment for the underlying BPPV itself 1
• These medications cause significant adverse effects including drowsiness, cognitive deficits, increased fall risk (especially in elderly patients), and interference with central compensation mechanisms 1, 2

Evidence from Clinical Trials

• A 2019 randomized controlled trial found that adding betahistine (24 mg twice daily for 10 days) or dimenhydrinate to CRP showed no superiority over CRP alone in reducing Dizziness Handicap Inventory scores 3
• A 2025 meta-analysis of 8 RCTs (516 participants) found that betahistine combined with Epley maneuver showed no clinically significant difference in DHI scores, VAS scores, or provocation maneuvers after 1 week of administration 4
• The same meta-analysis found only a statistically significant (but questionable clinical significance) reduction in VAS scores after 4 weeks of betahistine administration 4

When Betahistine Might Be Considered (Limited Scenarios)

Short-Term Use Only

• If betahistine is prescribed at all, it should be limited to 1-4 weeks maximum based on the available trial data 4, 5, 6
• One study used betahistine 24 mg twice daily for 10 days 3, while another used 8 mg three times daily for 4 weeks 6
• The typical European dosing is 16-48 mg three times daily, but this is for other vestibular conditions, not BPPV 2

Specific Patient Subgroups

• Betahistine may have limited efficacy in patients over 50 years old with hypertension and symptom onset less than 1 month, though this evidence is for general persistent dizziness, not BPPV specifically 2
• It might be considered in patients who are physically unable to undergo CRP due to severe cervical stenosis, morbid obesity, or other contraindications 1, 5
• One study suggested betahistine as sole therapy only when patients are "unfit to undergo canal repositioning maneuvers" 5

The Correct Treatment Algorithm for BPPV

First-Line: Canalith Repositioning Procedures

• Perform CRP (Epley maneuver) immediately upon diagnosis without any medications 1
• Success rates are 80% after 1-3 treatments and 90-98% with repeat maneuvers 1, 7
• Patients can resume normal activities immediately after CRP with no post-procedural restrictions 1

If Symptoms Persist After CRP

• Reassess within 1 month to confirm persistent BPPV, check for canal conversion (occurs in 6-7% of cases), or identify coexisting vestibular pathology 1
• Repeat CRP if diagnostic test remains positive—this achieves 90-98% success 1
• Consider vestibular rehabilitation therapy for residual dizziness, postural instability, or heightened fall risk after successful CRP 1, 2

Medication Role (If Any)

• Short-term vestibular suppressants (including betahistine) may be used only for severe nausea/vomiting during acute episodes, not as primary treatment 1
• Duration should be as brief as possible—typically 3-5 days maximum for acute symptom control 1
• Long-term use interferes with central compensation and may prolong symptoms 2

Critical Pitfalls to Avoid

• Do not prescribe betahistine as first-line therapy instead of performing CRP—this delays definitive treatment and increases fall risk during the untreated period 1
• Do not continue betahistine beyond 4 weeks even if used, as there is no evidence for longer duration and it may interfere with vestibular compensation 2, 4
• Do not use betahistine to prevent BPPV recurrence—recurrence rates are 10-18% at 1 year regardless of medication, and vestibular rehabilitation is more effective for prevention 1, 7
• Be especially cautious in elderly patients who have 12-fold increased fall risk with BPPV, and vestibular suppressants further increase this risk 1, 2